C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)

  Tucson, AZ – December 18, 2017  Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its first clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA) for the Symptoms of Major Depressive Disorder Scale (SMDDS). This qualification of the SMDDS for exploratory use represents a major milestone for the PRO … Continue reading C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)